Thromb Haemost 1970; 24(03/04): 475-486
DOI: 10.1055/s-0038-1654257
Originalarbeiten – Original Articles – Travaux Originaux
Schattauer GmbH

Immunological Identification of Two Urokinases[*]

Anne P Ball*)
1   Departments of Microbiology and Immunology and of Surgery, Duke University Medical Center, Durham, N.C.27706 (USA)
,
E. D Day
1   Departments of Microbiology and Immunology and of Surgery, Duke University Medical Center, Durham, N.C.27706 (USA)
› Author Affiliations
Further Information

Publication History

Publication Date:
28 June 2018 (online)

Summary

The two urokinase preparations currently undergoing clinical trials in the United States [Abbott urokinase (UK-A) and Sterling-Winthrop urokinase (UK-SW)] were compared immunologically using an antiserum prepared against UK-SW. Based on a previously described designation system, 2 components (III and IV) were found to be common to both preparations while the other two (I and II) detected by the antiserum were found only in UK-SW.

In order to relate functional activity to the immunological reactions seen in immunodiffusion and immunoelectrophoresis, inhibition titrations were carried out with simultaneous qualitative testing of the antigen-antibody mixtures. Two inflection points on the inhibition curve were correlated with the appearance of components III and IV in antigen excess or at equivalence. In the case of one globulin preparation (710) no plateau effect was observed, and components III and IV appeared in antigen excess at the same time.

The results of these studies indicate that 2 active components are present in both UK-A and UK-SW. These two are the components designated III and IV and are common to both preparations. The difference in equivalence points for these two components and those for inactive I and II make it possible to precipitate I and II completely while III and IV are in antigen excess, thus providing a reagent for identifying urokinase of either III- or IV- specificity in other samples.

*) Supported by Contract AT-(40-1)-3195 with the U.S. Atomic Energy Commission and by Grants HE-08929 and NB-06233 with the National Institutes of Health, USPHS.


**) This work is taken from adissertation submitted in partial fulfillment of the Ph .D. degree, Duke University . Present address, Department of Surgery , Duke University Medical Center.


 
  • References

  • 1 Ball Anne P. Dissertation, Urokinase: Immunochemical Analysis, Substrate Binding, and Mechanism of Fibrinolysis. (To be published in Dissertation Abstracts.)
  • 2 Day E. D, Ball A. P, Jeffords D, Woodard Jr W. T, Silver D. The immunoassay of human urokinase. Thrombos. Diathes. haemorrh. (Stuttg) 21: 273 1969;
  • 3 Kucinski D, Fletcher A, Sherry S. Effect of urokinase antiserum on plasminogen activators: Demonstration of immunologic dissimilarity between plasma plasminogen activator and urokinase. J. clin. Invest 47: 1238 1968;
  • 4 Ball Anne P, Day E. D. Urokinase-induced fibrinolysis of 125I-fibrin: Conditions for firstorder activation kinetics, density gradient separation of split products and a microassay. Thrombos. Diathes. haemorrh. (Stuttg) 24: 463 1970;
  • 5 White W. F, Barlow G. H, Mozen M. M. The isolation and characterization of plasminogen activators (Urokinase) from human urine. Biochemistry 05: 2160 1966;
  • 6 Lesuk A, Terminiello L, Traver J. H. Crystalline human urokinase: Some properties. Science 147: 880 1965;